Refine
Year of publication
- 2009 (1)
Document Type
- Doctoral Thesis (1)
Language
- English (1)
Has Fulltext
- yes (1)
Is part of the Bibliography
- no (1)
Keywords
- Gentransfer (1)
- Lentiviren (1)
- Pseudotypisierung (1)
- Transduktion B Zellen (1)
- genetransfer (1)
- lentiviral vectors (1)
- lentivirale Vektoren (1)
- pseudotyping (1)
- targeted cell entry (1)
- transduction B cells (1)
Institute
Lentiviral vectors mediate gene transfer into dividing and most non-dividing cells. Thereby, they stably integrate the transgene into the host cell genome. For this reason, lentiviral vectors are a promising tool for gene therapy. However, safety and efficiency of lentiviral mediated gene transfer still needs to be optimised. Ideally, cell entry should be restricted to the cell population relevant for a particular therapeutic application. Furthermore, lentiviral vectors able to transduce quiescent lymphocytes are desirable. Although many approaches were followed to engineer retroviral envelope proteins, an effective and universally applicable system for retargeting of lentiviral cell entry is still not available. Just before the experimental work of this thesis was started, retargeting of measles virus (MV) cell entry was achieved. This virus has two types of envelope glycoproteins, the hemagglutinin (H) protein responsible for receptor recognition and the fusion (F) protein mediating membrane fusion. For retargeting, the H protein was mutated in its interaction sites for the native MV receptors and a ligand or a single-chain antibody (scAb) was fused to its ectodomain. It was hypothesised that the retargeting system of MV can be transferred to lentiviral vectors by pseudotyping human immunodeficiency virus-1 (HIV-1) derived vector particles with the MV glycoproteins. As the unmodified MV glycoproteins did not pseudotype HIV vectors, two F and 15 H protein variants carrying stepwise truncations or amino acid (aa) exchanges in their cytoplasmic tails were screened for their ability to form MV-HIV pseudotypes. The combinations Hcd18/Fcd30, Hcd19/Fcd30 and Hcd24+4A/Fcd30 led to most efficient pseudotype formation with titers above 10exp6 transducing units /ml, using concentrated particles. The F cytoplasmic tail was truncated by 30 aa and the H cytoplasmic tail was truncated by 18, 19 or 24 residues with four added alanines after the start methionine in the latter case. Western blot analysis indicated that particle incorporation of the MV glycoproteins was enhanced upon truncation of their cytoplasmic tails. With the MV-HIV vectors high titers on different cell lines expressing one or both MV receptors were obtained, whereas MV receptor-negative cells remained untransduced. Titers were enhanced using an optimal H to F plasmid ratio (1:7) during vector particle production. Based on the described pseudotyping with the MV glycoprotein variants, HIV vectors retargeted to the epidermal growth factor receptor (EGFR) or the B cell surface marker CD20 were generated. For the production of the retargeted vectors MVaEGFR-HIV and MVaCD20-HIV, Fcd30 together with a native receptor blind Hcd18 protein, displaying at its ectodomain either the ligand EGF or a scAb directed against CD20 were used. With these vectors, gene transfer into target receptor-positive cells was several orders of magnitude more efficient than into control cells. The almost complete absence of background transduction of non-target cells was e.g. demonstrated in mixed cell populations, where the CD20-targeting vector selectively eliminated CD20-positive cells upon suicide gene transfer. Remarkably, transduction of activated primary human CD20-positive B cells was much more efficient with the MVaCD20-HIV vector than with the standard pseudotype vector VSV-G-HIV. Even more surprisingly, MVaCD20-HIV vectors were able to transduce quiescent primary human B cells, which until then had been resistant towards lentiviral gene transfer. The most critical step during the production of MV-HIV pseudotypes was the identification of H cytoplasmic tail mutants that allowed pseudotyping while retaining the fusion helper function. In contrast to previously inefficient targeting strategies, the reason for the success of this novel targeting system must be based on the separation of the receptor recognition and fusion functions onto two different proteins. Furthermore, with the CD20-targeting vector transduction of quiescent B cells was demonstrated for the first time. Own data and literature data suggest that CD20 binding and hyper-cross-linking by the vector particles results in calcium influx and thus activation of quiescent B cells. Alternatively this feature may be based on a residual binding activity of the MV glycoproteins to the native MV receptors that is insufficient for entry but induces cytoskeleton rearrangements dissolving the post-entry block of HIV vectors. Hence, in this thesis efficient retargeting of lentiviral vectors and transduction of quiescent cells was combined. This novel targeting strategy should be easily adaptable to many other target molecules by extending the modified MV H protein with appropriate specific domains or scAbs. It should now be possible to tailor lentiviral vectors for highly selective gene transfer into any desired target cell population with an unprecedented degree of efficiency.